- Home
- IFRX vs INMB Comparison
IFRX vs INMB Comparison
Compare IFRX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- INMB
- Stock Information
- Founded
- IFRX 2007
- INMB 2015
- Country
- IFRX Germany
- INMB United States
- Employees
- IFRX N/A
- INMB N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- INMB Health Care
- Exchange
- IFRX Nasdaq
- INMB Nasdaq
- Market Cap
- IFRX 53.5M
- INMB 49.2M
- IPO Year
- IFRX 2017
- INMB 2019
- Fundamental
- Price
- IFRX $1.26
- INMB $1.91
- Analyst Decision
- IFRX Strong Buy
- INMB Buy
- Analyst Count
- IFRX 5
- INMB 4
- Target Price
- IFRX $7.40
- INMB $9.53
- AVG Volume (30 Days)
- IFRX 486.5K
- INMB 396.2K
- Earning Date
- IFRX 11-07-2025
- INMB 11-06-2025
- Dividend Yield
- IFRX N/A
- INMB N/A
- EPS Growth
- IFRX N/A
- INMB N/A
- EPS
- IFRX N/A
- INMB N/A
- Revenue
- IFRX $191,224.00
- INMB $50,000.00
- Revenue This Year
- IFRX N/A
- INMB $191.43
- Revenue Next Year
- IFRX $1,216.24
- INMB $12,299.51
- P/E Ratio
- IFRX N/A
- INMB N/A
- Revenue Growth
- IFRX 54.36
- INMB N/A
- 52 Week Low
- IFRX $0.71
- INMB $1.71
- 52 Week High
- IFRX $2.82
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- IFRX 47.21
- INMB 43.87
- Support Level
- IFRX $1.14
- INMB $1.84
- Resistance Level
- IFRX $1.44
- INMB $2.00
- Average True Range (ATR)
- IFRX 0.14
- INMB 0.10
- MACD
- IFRX -0.04
- INMB 0.00
- Stochastic Oscillator
- IFRX 24.00
- INMB 33.40
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.